中国神经再生研究(英文版) ›› 2021, Vol. 16 ›› Issue (8): 1529-1530.doi: 10.4103/1673-5374.303024

• 观点:脑损伤修复保护与再生 • 上一篇    下一篇

缺血性卒中的组蛋白乙酰化和去乙酰化

  

  • 出版日期:2021-08-15 发布日期:2021-01-13

Histone acetylation and deacetylation in ischemic stroke

Anatoly B. Uzdensky*, Svetlana Demyanenko   

  1. Laboratory of Molecular Neurobiology, Academy of Biology and Biotechnology, Southern Federal University, Rostov-on-Don, Russia
  • Online:2021-08-15 Published:2021-01-13
  • Contact: Anatoly B. Uzdensky, PhD, auzd@yandex.ru.
  • Supported by:
    This work was funded by the grant of the Ministry of Science and Higher Education of the Russian Federation, No. 0852-2020-0028.  

摘要: https://orcid.org/0000-0002--0344-434x (Anatoly B. Uzdensky) 

Abstract: Stroke is the second leading cause of death in the world. A significant part of survived people become invalids, dependent on others and in need of outside care. This is a heavy burden for their families and society. The life of patients surviving ischemic stroke (~80% of all strokes) may be subdivided by three main phases: (a) The acute phase that lasts about first 24 hours, when the neurons may be saved and the neuroprotective therapy may be efficient; (b) The early recovery phase that lasts for several days and weeks, when the repair and regeneration processes develop, and partial recovery of brain functions occurs; and (c) The chronic phase (weeks, months and years), in which the organism state is stabilized and the patient gets the partial or full recovery. Different structural and functional modifications are possible throughout the whole post-stroke period, and the specific pharmacotherapy may be applied at each stage (Hankey, 2017).